San Diego-based genomics instrumentation pioneer Element Biosciences has finalized a 277 million Series D investment round, bringing its cumulative capital raised past680 million. The oversubscribed round was led by Wellington Management with substantial participation from Samsung E&A, Fidelity Management & Research Company, Venrock, and Foresite Capital.
Disrupting Next-Gen Sequencing Economics #
Element’s core market disruption centers on its proprietary Avidity Sequencing™ chemistry, which re-engineers traditional cyclic reversible terminator synthesis:
- Low-Concentration Multivalent Probes: Instead of single-nucleotide fluorescent labeling, Avidity chemistry uses low-affinity multivalent fluorescent polymer complexes that bind cooperatively with high avidity to repeated template clusters.
- Reduced Reagent Consumption: This thermodynamic avidity mechanism lowers reagent concentration requirements by > 80%, significantly reducing raw material consumable production costs.
- High-Fidelity Accuracy (Q40): Generates industry-leading sequencing accuracy with > 90% of bases scoring at or above Q40 (one error per 10,000 bases), outperforming standard Q30 metrics across complex GC-rich and repetitive genomic regions.
Head-to-Head Benchtop Sequencing Economics #
| Performance Metric | Element AVITI | Illumina NextSeq 2000 | Illumina NovaSeq X (Batch) |
|---|---|---|---|
| Sequencing Chemistry | Avidity Sequencing™ | XLEAP-SBS | Standard SBS |
| Base Quality Standard | > 90% ge ext{Q40} | > 85% ge ext{Q30} | > 85% ge ext{Q30} |
| Throughput per Flow Cell | Up to 1.0 Billion reads (300 Gb) | Up to 1.2 Billion reads (360 Gb) | Up to 16 Billion reads |
| Cost Per Human Genome (30 imes) | 200 (Single pair runs) | 500–650 | 200 (Requires 128-sample batch) |
| Dual Flow Cell Flexibility | Completely independent run start | Single flow cell operational slot | High-batch flow cell staging |
Commercial Growth & The AVITI24 Architecture #
The newly secured capital will accelerate commercial manufacturing and global field support for two flagship platforms:
- Installed Base Momentum: The global installed base of AVITI benchtop instruments has expanded beyond 450 active units across academic genome centers, clinical molecular pathology laboratories, and biopharmaceutical contract research organizations (CROs).
- AVITI24 Multi-Omics Platform: Significant investment is directed toward scaling the AVITI24 system, an innovative instrument that integrates high-throughput short-read NGS with in situ single-cell spatial transcriptomics, RNA profiling, and cell morphology characterization on a single benchtop instrument.
- Global Service Footprint: Capital provides financial runway to expand direct sales channels, certified field application scientist (FAS) teams, and rapid-response technical service hubs across Western Europe, Japan, South Korea, and Singapore.
Industry Leadership & Market Dynamics #
"This substantial capital infusion validates that sequencing customers are demanding independent multi-vendor optionality, lower per-run operational costs, and higher analytical fidelity," commented Dr. Marcus Vance, Director of Capital Equipment & Automation at BioScienceDesk. "By decoupling high-throughput sequencing from massive, capital-intensive instruments, Element has democratized $200 human genomes for mid-sized regional laboratories."
Molly He, Ph.D., CEO and Co-founder of Element Biosciences, emphasized in the financing announcement: "Our vision has always been to break the trade-offs between sequencing quality, operational flexibility, and affordability. With the AVITI24, we are unifying genomics and spatial biology, enabling researchers to interrogate genetic sequence, spatial localization, and functional cell phenotypes in a single experiment."
Competitive Landscape Against Illumina & Complete Genomics #
The Series D financing positions Element to challenge Illumina’s long-standing dominant market share, particularly in academic core facilities and mid-sized clinical genomics laboratories evaluating capital equipment upgrades. With Illumina countering through its MiSeq i100 benchtop platform, competitive price pressure is delivering unprecedented cost reductions to researchers worldwide.